Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 8/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 3/20 | 0.36 |
| ▸ | CDK8 | P49336 | 3/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347041 | 0.88 | ALDH1A1 (0.38) | GRM1KMT2AGSK3B | |
| SCHEMBL2340570 | 0.85 | ALDH1A1 (0.37) | KDM4EKMT2A | |
| SCHEMBL4699630 | 0.84 | ALPL (0.40) | KDM4EKMT2A | |
| SCHEMBL4704289 | 0.77 | MCL1 (0.43) | KDM4EKMT2A | |
| SCHEMBL4702321 | 0.73 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL4788586 | 0.73 | GRM1 (0.43) | GRM1ROCK2KDM4EKMT2A | |
| SCHEMBL4702012 | 0.72 | NOS1 (0.47) | — | |
| SCHEMBL27564497 | 0.71 | PAX8 (0.46) | KMT2A | |
| SCHEMBL4758474 | 0.70 | GRM1 (0.43) | GRM1ROCK2ROCK1CDC7DBF4 | |
| SCHEMBL17794330 | 0.69 | PIN1 (0.41) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | GRM1 3978/4885ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.